ESTRO 2025 - Abstract Book

S4384

RTT - Treatment planning, OAR and target definitions

ESTRO 2025

Results: CTV Coverage was: V95 median= 97.7% (IQR 96.5-98.6 %); median maximum dose was 110.3%. All dose constraints (Fast Forward Study protocol) to organs at risk were respected. The dosimetric results of this retrospective analysis are shown in Table 2. In particular for left breast cancer treatments the mean of Dmean whole heart=1,36 Gy, V7= 3.51%, V1.5= 11.75%, of Dmean LAD=5,03 Gy, Dmean LV=2,19 Gy, V4.2=7,8 %, V15,1=4,3% Our preliminary results are in agreement with those present in the literature (1,2) All pts completed treatment with excellent compliance. Median follow-up was 22 months (IQR 20-23.3), range: 18-35 months. A very low toxicity profile was observed (CTCAE V 4.0): there were no ≥ G2 acute/late reactions. No cardiac events were reported.